Obesity, immunomodulation and chronic kidney disease

Emma Börgeson, Kumar Sharma

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

Obesity-induced inflammation is associated with numerous pathologies and is an independent risk factor of chronic kidney disease (CKD). The prevalence of CKD is escalating and current therapeutic strategies are seriously lacking in efficacy, and immunomodulation has been suggested as a potential new therapeutic approach. Indeed, specialized pro-resolving mediators (SPMs), such as lipoxins (LXs), resolvins and protectins, have demonstrated protection in adipose inflammation, restoring insulin sensitivity and adiponectin production, while modulating leukocyte infiltration and promoting resolution in visceral adipose tissue. Furthermore, SPMs display direct renoprotective effect. Thus we review current evidence of immunomodulation as a potential strategy to subvert obesity-related CKD.

Original languageEnglish (US)
Pages (from-to)618-624
Number of pages7
JournalCurrent Opinion in Pharmacology
Volume13
Issue number4
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this